Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer ...

The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics. Each of their ...

AstraZeneca and partner Merck & Co look set to have a much narrower label for their PARP inhibitor Lynparza in prostate cancer than they were hoping for in the US. The FDA’s Oncologic Drugs ...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market share.

The MEDIOLA trial evaluated olaparib (Lynparza) and durvalumab (Imfinzi) with or without bevacizumab in recurrent ovarian cancer and showed a 34% response rate with the PARP inhibitor and the PD-L1 ...

PARP inhibitor Lynparza (olaparib) is a targeted treatment option that has been studied in early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with MSD (Merck & Co ...

Patients with platinum-sensitive relapsed ovarian cancer given maintenance olaparib/cediranib had similar progression-free ...

In March, the company reported that a late-stage study evaluating the combination of Keytruda and Lynparza in metastatic non-squamous NSCLC indication failed to meet its primary endpoints.

Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an ...

In recent months, the Keytruda-Astraeneca Lynparza combination and Keytruda with Eisai's Lenvima also failed separate trials as cancer treatments. Keytruda belongs to a class of medicines called ...